Evercore ISI raises BioMarin stock price target on valuation gap By Investing.com

Evercore ISI raised BioMarin's price target to $120 from $110 while maintaining an Outperform rating, citing a valuation disconnect and upcoming catalysts. BioMarin's Q1 2026 results beat expectations with EPS of $0.76 versus $0.74 consensus and revenue of $766 million versus $755.94 million, while patients treated with Voxzogo rose 20% year over year. The company also updated revenue guidance to reflect its FOLD acquisition, and shares may be supported by more cash than debt on the balance sheet.

Analysis

The market is still treating BMRN like a mature rare-disease cash flow story, but the setup is more like a transition into a multi-catalyst re-rate. The key second-order dynamic is not just continued Voxzogo durability; it’s that switching friction in ultra-rare pediatric markets tends to be stickier than consensus models assume, which can keep the revenue base intact long enough for pipeline optionality to matter. That combination is valuable because it reduces the probability that incremental share gains elsewhere meaningfully offset the franchise before the next wave of data.

The real asymmetry is on the balance sheet and the timeline. With net cash and multiple readouts clustered over the next 12-18 months, the company has enough financial runway to avoid “prove-it-now” compression, which lowers dilution risk and supports valuation expansion if even one late-stage program lands. The market is likely underpricing the probability that investors start to pay for 2027-2028 earnings power today once BMN 333 and the Phase 3 catalysts create a visible sequence of decision points.

The contrarian risk is that the stock may already be pricing in a clean catalyst path while ignoring execution drag from the FOLD integration and the possibility that near-term enthusiasm around Voxzogo masks a flattening growth slope. If upcoming data are merely acceptable rather than clearly superior, the multiple can stay trapped despite solid fundamentals. In that sense, the stock is less a binary biotech than a time-decay trade: the longer the pipeline stays alive without disappointment, the more the valuation disconnect can close.

From a relative-value perspective, BMRN looks better as a low-volatility long versus other biotech names with similar event risk but weaker balance sheets. The cleanest expression is to buy downside-insulated exposure into the next catalyst window, because realized volatility should rise as those data dates approach and the market starts repricing outcome dispersion rather than current-quarter fundamentals.

Key Decisions for Investors

• Initiate a medium-term long in BMRN ahead of the 2Q26 catalyst window; target 15-25% upside if pipeline data are simply good enough to validate re-rating, with ~10-12% downside if the market re-anchors on execution risk.
• Use call spreads in BMRN rather than outright common stock for the next 6-9 months; upside is driven by catalyst convexity, while downside is cushioned by the existing cash position and current revenue base.
• Pair trade: long BMRN / short a basket of higher-burn, event-heavy biotech names over the next 3-6 months; favor names with weaker balance sheets where any data disappointment forces de-rating faster than in BMRN.
• If the stock rallies sharply into the first catalyst date, trim into strength and keep a residual position for the second readout; the setup is sequential, not one-and-done.
• For more aggressive positioning, buy 2026-2027 upside calls on BMRN only if implied vol stays below historical event-driven levels; otherwise prefer stock plus protective puts for better risk/reward.